Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

QR Pharma to Study Posiphen

October 18, 2011 12:27 pm | News | Comments

QR Pharma, Inc., along with the Medical University of South Carolina obtained results from a Phase 1 grant study on Posiphen.


Nycomed Appoints New Head of Emerging Markets

October 18, 2011 12:23 pm | News | Comments

Nycomed appointed Jostein Davidsen as Head of Emerging Markets.


Prolonged Survival in Lung Cancer Patients With Diabetes

October 18, 2011 12:21 pm | News | Comments

Lung cancer patients with diabetes tend to live longer than patients without diabetes, according to a Norwegian study.


Possible Link Between Bacterium, Colon Cancer

October 18, 2011 12:16 pm | News | Comments

Scientists at Dana-Farber Cancer Institute and the Broad Institute have found high levels of a bacterium in colorectal cancers.


Breast Cancer Protein Emerges as Drug Target

October 18, 2011 12:09 pm | News | Comments

A protein in the nucleus of breast cancer cells that plays a role in fueling the growth of aggressive tumors may be a good target for new drugs.


BacMam Reagents

October 18, 2011 8:08 am | Product Releases | Comments

Life Technologies has launched BacMam LRRK2-GFP Reagents. BacMam LRRK2-GFP provides researchers a tool to assess LRKK2 chemical response and visualize its expression in a variety of cell backgrounds.


Western Diluent

October 18, 2011 8:02 am | Drug Discovery & Development | Product Releases | Comments

G-Biosciences' Swift Western Diluent is a unique, single reagent solution that reduces the blocking and antibody incubations on Western blot membranes from over 4 hours to less than 60 minutes.


Affitech and GE Sign License Agreement

October 18, 2011 7:53 am | News | Comments

Affitech A/S and GE Healthcare Life Sciences announced an exclusive license for the worldwide marketing and sales of products containing recombinant Protein L, granted by Affitech in a patent and know-how license agreement.


Potential Target for Pulmonary Hypertension Found

October 18, 2011 7:37 am | News | Comments

A protein critical to development appears to have a grave impact on lungs exposed to smoking and air pollution. Blocking that protein in the lungs may prove an effective way to avoid narrow, scarred blood vessels and pulmonary hypertension.


TAK-875 Begins Phase 3 Trial

October 18, 2011 7:30 am | News | Comments

Takeda Pharmaceutical Company Limited has initiated a Phase 3 clinical trial program for TAK-875, an investigational therapy for type 2 diabetes. TAK-875 is the first GPR40 agonist to reach Phase 3 clinical development.


FDA Approves Ferriprox

October 18, 2011 7:06 am | News | Comments

The U.S. Food and Drug Administration approved deferiprone to treat patients with iron overload due to blood transfusions in patients with thalassemia, a genetic blood disorder that causes anemia, who had an inadequate response to prior chelation therapy.


Immune Cell Plays Dual Role in Dermatitis

October 18, 2011 6:52 am | News | Comments

An immune cell involved in initiating the symptoms of an allergic skin reaction may play an equally, or perhaps more important, role in suppressing the reaction once it becomes chronic.


Eli Lilly to Report 3Q Earnings

October 18, 2011 6:49 am | News | Comments

On October 20, drugmaker Eli Lilly and Co. will report results from its last full quarter before losing U.S. patent protection for its top-selling drug, the antipsychotic Zyprexa.


J & J Profits Off 6%

October 18, 2011 6:41 am | by Linda A. Johnson | News | Comments

Johnson & Johnson's third-quarter profit fell 6 percent because larger overhead and production costs and a one-time charge offset higher foreign sales.


No Needles Required for New Gene Therapy

October 17, 2011 11:38 am | News | Comments

For the first time, researchers have found a way to inject a precise dose of a gene therapy agent directly into a single living cell without a needle. The technique uses electricity to shoot bits of therapeutic biomolecules into the cell.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.